JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement

[ad_1] AbbVie has bought the rights to RemeGen’s PD-1/VEGF bispecific, RC148, for up to $5.6bn amid the ongoing J.P. Morgan 2026 Healthcare Conference. Image credit: Skorzewiak via ShutterStock.com. AbbVie and RemeGen have signed the first deal of the J.P Morgan Healthcare Conference 2026, with the companies agreeing to an exclusive oncology licensing agreement. The oncology-focused…

Read More

JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax

[ad_1] An Eli Lilly spokesperson told Pharmaceutical Technology that the comapny “does not comment on business development activity.” JHVEPhoto via Shutterstock.com. Eli Lilly is reportedly looking to acquire French biotech Abivax, sending the latter company’s shares surging ahead of the J.P. Morgan Healthcare Conference 2026. According to a report by French news outlet La Lettre…

Read More